Mostrar el registro sencillo del ítem
dc.contributor.author
Feijó Azevedo, Valderilio
dc.contributor.author
Babini, Alejandra
dc.contributor.author
Vieira Teixeira, Fabio
dc.contributor.author
Age Kos, Igor
dc.contributor.author
Matar, Pablo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2019-07-11T18:16:01Z
dc.date.issued
2016-06
dc.identifier.citation
Feijó Azevedo, Valderilio; Babini, Alejandra; Vieira Teixeira, Fabio; Age Kos, Igor; Matar, Pablo; New monoclonal antibody biosimilars approved in 2015 in Latin America: Position statement of the Latin American Forum on Biosimilars in biosimilarity, interchangeability and extrapolation of indications; Pro Pharma Communications International; Generics and Biosimilars Initiative Journal; 5; 2; 6-2016; 66-69
dc.identifier.issn
2033-6403
dc.identifier.uri
http://hdl.handle.net/11336/79369
dc.description.abstract
Introduction: The Latin American Forum on Biosimilars (FLAB) is an annual meeting that brings together various stakeholders, including key opinion leaders, the pharmaceutical industry, academics, patients, lawyers and other healthcare professionals, to present and discuss recent findings regarding biosimilars. In 2015, the meeting theme was interchangeability and automatic substitution. Regarding biosimilarity, interchangeability and extrapolation of indications, the discussion centred on two products in Brazil and Argentina: CT-P13, an infliximab biosimilar; and RTXM83, a rituximab biosimilar. Here, we conduct a critical analysis of the available scientific and medical information on these products to establish a FLAB position statement in the context of the current regulations in Brazil and Argentina. Biosimilarity, interchangeability and extrapolation of indications: RTXM83 is still not approved in Brazil and is currently under a technology transfer agreement. In Argentina, the drug was approved for commercialization under the name Novex, with extrapolation of indications for rheumatoid arthritis, which according to the Argentinian Society of Rheumatology, lacks the necessary clinical data for such an approval. CT-P13 is already approved in Brazil, and is on the market. The approval was based on the data presented in the PLANETAS and PLANETRA studies. Interchangeability will not be considered for this product until further studies are presented. Discussion: Based on the available evidence, CT-P13 is the only biological molecule marketed in Latin America that can be considered a true biosimilar. Extrapolation is only acceptable when the diseases for which the reference product is intended to treat are entirely similar. Extrapolation based on only preclinical studies is not acceptable. Conversely, although the proposed rituximab biosimilar (RTXM83) was approved by ANMAT (National Administration for Medicines, Food and Medical Technology) in Argentina, clinical data demonstrating its equivalence with the reference rituximab, is necessary before RTXM83 can be considered a true biosimilar.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Pro Pharma Communications International
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Biosimilarity
dc.subject
Extrapolation
dc.subject
Infliximab
dc.subject
Interchangeability
dc.subject
Monoclonal Antibodies
dc.subject
Rituximab
dc.subject.classification
Otras Biotecnologías de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Biotecnología de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
New monoclonal antibody biosimilars approved in 2015 in Latin America: Position statement of the Latin American Forum on Biosimilars in biosimilarity, interchangeability and extrapolation of indications
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-06-11T15:21:07Z
dc.identifier.eissn
2033-6772
dc.journal.volume
5
dc.journal.number
2
dc.journal.pagination
66-69
dc.journal.pais
Bélgica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Mol
dc.description.fil
Fil: Feijó Azevedo, Valderilio. Universidade Federal do Paraná; Brasil. Health Research and Educational Center; Brasil
dc.description.fil
Fil: Babini, Alejandra. Hospital Italiano Córdoba; Argentina. Sociedad Argentina de Reumatología; Argentina
dc.description.fil
Fil: Vieira Teixeira, Fabio. Clínica Gastrosaude de Marilia; Brasil. Grupo de Estudos de Doença Inflamatória Intestinal; Brasil
dc.description.fil
Fil: Age Kos, Igor. Universidade Federal do Paraná; Brasil. Health Research and Educational Center; Brasil
dc.description.fil
Fil: Matar, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina
dc.journal.title
Generics and Biosimilars Initiative Journal
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.5639/gabij.2016.0502.017
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://gabi-journal.net/new-monoclonal-antibody-biosimilars-approved-in-2015-in-latin-america-position-statement-of-the-latin-american-forum-on-biosimilars-on-biosimilarity-interchangeability-and-extrapolation-of-indications.html
Archivos asociados